Graft Versus Host Disease - prIME Oncology
Expert Review
Expert Review

Graft Versus Host Disease

Not a member of My prIME? Join now for instant access.

Learn from experts and benefit your patients with graft versus host disease (GVHD). This CME-certified discussion features and expert discussion, downloadable slides, and clinical questions focusing on recent GVHD diagnostic criteria and emerging clinical data for novel methods of targeting the immune system as treatment strategies.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.75 AMA PRA Category 1 Credits

CE

CE

1.7 Contact Hours

Release Date

Release Date

Aug 9, 2017

Expiration Date

Aug 9, 2018

  • Corey Cutler, MD, MPH, FACP(C)Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • David Miklos, MD, PhDStanford University
    Stanford, California, United States
  • Diagnostic criteria for chronic GVHD
  • Steroids for chronic GVHD
  • Trials for steroid-refractory chronic GVHD
  • Supportive care needs for chronic GVHD
  • Novel agents being investigated for acute GVHD

This educational activity is specifically designed for physicians and registered nurses who comprise the core hematopoietic stem cell transplantation team, as well as community-based oncology physicians and nurses.

After successful completion of this educational activity, participants should be able to:

  • Explain the pathophysiology of acute GVHD, as well as the more recent understanding of the biology of chronic GVHD
  • Evaluate the potential clinical utility of data on diagnostic and prognostic markers of GVHD
  • Utilize treatment and management strategies incorporating new targeted therapies for acute and chronic GVHD based on an understanding of the mechanism of action, benefits, risks, dosing, monitoring, and management of the agents

This activity is supported by educational grants from Incyte, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Continuing Education

Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Graft Versus Host Disease - prIME Oncology

Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

A maximum of 1.7 contact hours may be earned for successful completion of this activity.

Annenberg Center for Health Sciences: www.annenberg.net

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Annenberg Center policy.  Annenberg Center is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Cutler has disclosed that he has received consulting fees from Incyte and Pharmacyclics. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Miklos has disclosed that he has received consulting fees from Adaptive Biotechnologies and Pharmacyclics. He also performed contracted research for Pharmacyclics. He has a patent with PCYC regarding GVHD and ibrutinib. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Elizabeth Cameron, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships

Charles W. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.